Hologic Net Worth
Hologic Net Worth Breakdown | HOLX |
Hologic Net Worth Analysis
Hologic's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Hologic's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Hologic's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Hologic's net worth analysis. One common approach is to calculate Hologic's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Hologic's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Hologic's net worth. This approach calculates the present value of Hologic's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Hologic's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Hologic's net worth. This involves comparing Hologic's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Hologic's net worth relative to its peers.
Enterprise Value |
|
To determine if Hologic is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Hologic's net worth research are outlined below:
Hologic generated a negative expected return over the last 90 days | |
Over 99.0% of the company shares are owned by institutional investors | |
Latest headline from thelincolnianonline.com: Parnassus Investments LLC Reduces Stock Position in Hologic, Inc. |
Hologic Quarterly Good Will |
|
Hologic uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Hologic. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Hologic's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
1st of February 2024 Upcoming Quarterly Report | View | |
6th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
14th of November 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
30th of September 2023 Last Financial Announcement | View |
Hologic Target Price Consensus
Hologic target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Hologic's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
21 | Buy |
Most Hologic analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Hologic stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Hologic, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationHologic Target Price Projection
Hologic's current and average target prices are 60.71 and 85.44, respectively. The current price of Hologic is the price at which Hologic is currently trading. On the other hand, Hologic's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Hologic Target Price
Know Hologic's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Hologic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Hologic backward and forwards among themselves. Hologic's institutional investor refers to the entity that pools money to purchase Hologic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Boston Partners Global Investors, Inc | 2024-12-31 | 3.6 M | Ameriprise Financial Inc | 2024-12-31 | 3.5 M | Northern Trust Corp | 2024-12-31 | 3.1 M | Macquarie Group Ltd | 2024-12-31 | 3 M | Bank Of America Corp | 2024-12-31 | 2.8 M | Hsbc Holdings Plc | 2024-12-31 | 2.8 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 2.6 M | Alliancebernstein L.p. | 2024-12-31 | 2.6 M | Renaissance Technologies Corp | 2024-12-31 | 2.5 M | Vanguard Group Inc | 2024-12-31 | 26.9 M | Blackrock Inc | 2024-12-31 | 22.2 M |
Follow Hologic's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.7 B.Market Cap |
|
Project Hologic's profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.09 | 0.10 | |
Return On Capital Employed | 0.08 | 0.08 | |
Return On Assets | 0.05 | 0.04 | |
Return On Equity | 0.09 | 0.10 |
When accessing Hologic's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Hologic's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Hologic's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Hologic's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Hologic. Check Hologic's Beneish M Score to see the likelihood of Hologic's management manipulating its earnings.
Evaluate Hologic's management efficiency
Hologic has return on total asset (ROA) of 0.071 % which means that it generated a profit of $0.071 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1578 %, meaning that it created $0.1578 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Hologic's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.1 in 2025, whereas Return On Capital Employed is likely to drop 0.08 in 2025. At this time, Hologic's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 4.6 B in 2025, whereas Non Current Assets Total are likely to drop slightly above 3.1 B in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 20.33 | 21.35 | |
Tangible Book Value Per Share | 3.43 | 3.60 | |
Enterprise Value Over EBITDA | 15.51 | 16.28 | |
Price Book Value Ratio | 3.41 | 3.24 | |
Enterprise Value Multiple | 15.51 | 16.28 | |
Price Fair Value | 3.41 | 3.24 | |
Enterprise Value | 1.9 B | 2 B |
The decision-making processes within Hologic are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 3.5122 | Revenue | Quarterly Revenue Growth 0.009 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hologic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hologic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hologic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hologic Corporate Filings
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
14th of February 2025 Other Reports | ViewVerify | |
F4 | 12th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 6th of February 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Hologic Earnings Estimation Breakdown
The calculation of Hologic's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Hologic is estimated to be 1.0168 with the future projection ranging from a low of 1.0 to a high of 1.03. Please be aware that this consensus of annual earnings estimates for Hologic is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.00 Lowest | Expected EPS | 1.03 Highest |
Hologic Earnings Projection Consensus
Suppose the current estimates of Hologic's value are higher than the current market price of the Hologic stock. In this case, investors may conclude that Hologic is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Hologic's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
21 | 90.49% | 1.03 | 1.0168 | 3.16 |
Hologic Earnings History
Earnings estimate consensus by Hologic analysts from Wall Street is used by the market to judge Hologic's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Hologic's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Hologic Quarterly Gross Profit |
|
Hologic Earnings per Share Projection vs Actual
Actual Earning per Share of Hologic refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Hologic predict the company's earnings will be in the future. The higher the earnings per share of Hologic, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Hologic Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Hologic, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Hologic should always be considered in relation to other companies to make a more educated investment decision.Hologic Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Hologic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2025-01-30 | 2024-12-31 | 1.0159 | 1.03 | 0.0141 | 1 | ||
2024-11-04 | 2024-09-30 | 1.01 | 1.01 | 0.0 | 0 | ||
2024-07-29 | 2024-06-30 | 1.02 | 1.06 | 0.04 | 3 | ||
2024-05-02 | 2024-03-31 | 0.98 | 1.03 | 0.05 | 5 | ||
2024-02-01 | 2023-12-31 | 0.95 | 0.98 | 0.03 | 3 | ||
2023-11-09 | 2023-09-30 | 0.84 | 0.89 | 0.05 | 5 | ||
2023-07-31 | 2023-06-30 | 0.89 | 0.93 | 0.04 | 4 | ||
2023-05-01 | 2023-03-31 | 0.88 | 1.06 | 0.18 | 20 | ||
2023-02-01 | 2022-12-31 | 0.91 | 1.07 | 0.16 | 17 | ||
2022-10-31 | 2022-09-30 | 0.62 | 0.82 | 0.2 | 32 | ||
2022-07-27 | 2022-06-30 | 0.71 | 0.95 | 0.24 | 33 | ||
2022-04-27 | 2022-03-31 | 1.6 | 2.07 | 0.47 | 29 | ||
2022-02-02 | 2021-12-31 | 1.28 | 2.17 | 0.89 | 69 | ||
2021-11-01 | 2021-09-30 | 1.01 | 1.61 | 0.6 | 59 | ||
2021-07-28 | 2021-06-30 | 1.12 | 1.33 | 0.21 | 18 | ||
2021-04-28 | 2021-03-31 | 2.62 | 2.59 | -0.03 | 1 | ||
2021-01-27 | 2020-12-31 | 2.17 | 2.86 | 0.69 | 31 | ||
2020-11-04 | 2020-09-30 | 1.22 | 2.07 | 0.85 | 69 | ||
2020-07-29 | 2020-06-30 | 0.39 | 0.75 | 0.36 | 92 | ||
2020-04-29 | 2020-03-31 | 0.57 | 0.57 | 0.0 | 0 | ||
2020-01-29 | 2019-12-31 | 0.61 | 0.61 | 0.0 | 0 | ||
2019-11-06 | 2019-09-30 | 0.65 | 0.65 | 0.0 | 0 | ||
2019-07-31 | 2019-06-30 | 0.61 | 0.63 | 0.02 | 3 | ||
2019-05-01 | 2019-03-31 | 0.57 | 0.58 | 0.01 | 1 | ||
2019-01-30 | 2018-12-31 | 0.57 | 0.58 | 0.01 | 1 | ||
2018-11-07 | 2018-09-30 | 0.58 | 0.58 | 0.0 | 0 | ||
2018-07-31 | 2018-06-30 | 0.56 | 0.58 | 0.02 | 3 | ||
2018-05-02 | 2018-03-31 | 0.53 | 0.53 | 0.0 | 0 | ||
2018-02-08 | 2017-12-31 | 0.5 | 0.55 | 0.05 | 10 | ||
2017-11-08 | 2017-09-30 | 0.49 | 0.5 | 0.01 | 2 | ||
2017-08-02 | 2017-06-30 | 0.49 | 0.5 | 0.01 | 2 | ||
2017-05-10 | 2017-03-31 | 0.46 | 0.5 | 0.04 | 8 | ||
2017-02-01 | 2016-12-31 | 0.51 | 0.52 | 0.01 | 1 | ||
2016-11-02 | 2016-09-30 | 0.5 | 0.52 | 0.02 | 4 | ||
2016-07-27 | 2016-06-30 | 0.48 | 0.51 | 0.03 | 6 | ||
2016-04-27 | 2016-03-31 | 0.46 | 0.47 | 0.01 | 2 | ||
2016-01-27 | 2015-12-31 | 0.42 | 0.46 | 0.04 | 9 | ||
2015-11-04 | 2015-09-30 | 0.42 | 0.43 | 0.01 | 2 | ||
2015-07-29 | 2015-06-30 | 0.39 | 0.43 | 0.04 | 10 | ||
2015-04-29 | 2015-03-31 | 0.39 | 0.41 | 0.02 | 5 | ||
2015-01-28 | 2014-12-31 | 0.36 | 0.39 | 0.03 | 8 | ||
2014-11-05 | 2014-09-30 | 0.37 | 0.43 | 0.06 | 16 | ||
2014-07-30 | 2014-06-30 | 0.34 | 0.37 | 0.03 | 8 | ||
2014-04-30 | 2014-03-31 | 0.33 | 0.37 | 0.04 | 12 | ||
2014-02-03 | 2013-12-31 | 0.31 | 0.34 | 0.03 | 9 | ||
2013-11-11 | 2013-09-30 | 0.37 | 0.39 | 0.02 | 5 | ||
2013-08-05 | 2013-06-30 | 0.37 | 0.38 | 0.01 | 2 | ||
2013-05-06 | 2013-03-31 | 0.34 | 0.35 | 0.01 | 2 | ||
2013-02-04 | 2012-12-31 | 0.37 | 0.38 | 0.01 | 2 | ||
2012-11-12 | 2012-09-30 | 0.37 | 0.37 | 0.0 | 0 | ||
2012-07-30 | 2012-06-30 | 0.34 | 0.35 | 0.01 | 2 | ||
2012-04-30 | 2012-03-31 | 0.33 | 0.33 | 0.0 | 0 | ||
2012-01-30 | 2011-12-31 | 0.32 | 0.34 | 0.02 | 6 | ||
2011-11-07 | 2011-09-30 | 0.33 | 0.34 | 0.01 | 3 | ||
2011-08-01 | 2011-06-30 | 0.32 | 0.32 | 0.0 | 0 | ||
2011-05-02 | 2011-03-31 | 0.28 | 0.3 | 0.02 | 7 | ||
2011-01-31 | 2010-12-31 | 0.28 | 0.3 | 0.02 | 7 | ||
2010-11-08 | 2010-09-30 | 0.3 | 0.3 | 0.0 | 0 | ||
2010-08-02 | 2010-06-30 | 0.29 | 0.3 | 0.01 | 3 | ||
2010-05-03 | 2010-03-31 | 0.29 | 0.29 | 0.0 | 0 | ||
2010-02-01 | 2009-12-31 | 0.26 | 0.29 | 0.03 | 11 | ||
2009-11-09 | 2009-09-30 | 0.27 | 0.28 | 0.01 | 3 | ||
2009-08-03 | 2009-06-30 | 0.26 | 0.29 | 0.03 | 11 | ||
2009-05-04 | 2009-03-31 | 0.27 | 0.29 | 0.02 | 7 | ||
2009-02-02 | 2008-12-31 | 0.29 | 0.31 | 0.02 | 6 | ||
2008-11-11 | 2008-09-30 | 0.3 | 0.3 | 0.0 | 0 | ||
2008-07-30 | 2008-06-30 | 0.29 | 0.33 | 0.04 | 13 | ||
2008-05-01 | 2008-03-31 | 0.28 | 0.29 | 0.01 | 3 | ||
2008-01-31 | 2007-12-31 | 0.24 | 0.26 | 0.02 | 8 | ||
2007-11-06 | 2007-09-30 | 0.23 | 0.29 | 0.06 | 26 | ||
2007-07-31 | 2007-06-30 | 0.21 | 0.23 | 0.02 | 9 | ||
2007-05-01 | 2007-03-31 | 0.18 | 0.2 | 0.02 | 11 | ||
2007-01-31 | 2006-12-31 | 0.12 | 0.15 | 0.03 | 25 | ||
2006-11-08 | 2006-09-30 | 0.1 | -0.01 | -0.11 | 110 | ||
2006-07-25 | 2006-06-30 | 0.13 | 0.13 | 0.0 | 0 | ||
2006-04-25 | 2006-03-31 | 0.1 | 0.12 | 0.02 | 20 | ||
2006-01-24 | 2005-12-31 | 0.07 | 0.06 | -0.01 | 14 | ||
2005-11-02 | 2005-09-30 | 0.09 | 0.1 | 0.01 | 11 | ||
2005-07-27 | 2005-06-30 | 0.07 | 0.09 | 0.02 | 28 | ||
2005-04-27 | 2005-03-31 | 0.06 | 0.07 | 0.01 | 16 | ||
2005-01-26 | 2004-12-31 | 0.02 | 0.05 | 0.03 | 150 | ||
2004-11-10 | 2004-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
2004-08-03 | 2004-06-30 | 0.04 | 0.04 | 0.0 | 0 | ||
2004-05-04 | 2004-03-31 | 0.03 | 0.03 | 0.0 | 0 | ||
2004-02-03 | 2003-12-31 | 0.01 | 0.01 | 0.0 | 0 | ||
2003-11-12 | 2003-09-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2003-08-06 | 2003-06-30 | 0.01 | 0.01 | 0.0 | 0 | ||
2003-02-04 | 2002-12-31 | 0.01 | -0.01 | -0.02 | 200 | ||
2002-11-12 | 2002-09-30 | 0.01 | -0.04 | -0.05 | 500 | ||
2002-08-01 | 2002-06-30 | 0.01 | 0.01 | 0.0 | 0 | ||
2002-05-02 | 2002-03-31 | 0.02 | 0.06 | 0.04 | 200 | ||
2002-02-05 | 2001-12-31 | -0.06 | -0.02 | 0.04 | 66 | ||
2001-11-14 | 2001-09-30 | -0.04 | -0.06 | -0.02 | 50 | ||
2001-08-13 | 2001-06-30 | -0.1 | -0.1 | 0.0 | 0 | ||
2000-11-16 | 2000-09-30 | -0.04 | -0.04 | 0.0 | 0 | ||
2000-08-01 | 2000-06-30 | -0.03 | -0.04 | -0.01 | 33 | ||
2000-04-27 | 2000-03-31 | -0.04 | -0.04 | 0.0 | 0 | ||
2000-01-27 | 1999-12-31 | -0.05 | -0.05 | 0.0 | 0 | ||
1999-11-08 | 1999-09-30 | -0.04 | -0.0518 | -0.0118 | 29 | ||
1999-07-29 | 1999-06-30 | 0.01 | -0.01 | -0.02 | 200 | ||
1999-04-29 | 1999-03-31 | 0.05 | -0.02 | -0.07 | 140 | ||
1999-01-28 | 1998-12-31 | 0.06 | 0.04 | -0.02 | 33 | ||
1998-11-09 | 1998-09-30 | 0.08 | 0.03 | -0.05 | 62 | ||
1998-07-30 | 1998-06-30 | 0.09 | 0.08 | -0.01 | 11 | ||
1998-04-29 | 1998-03-31 | 0.07 | 0.05 | -0.02 | 28 | ||
1998-02-03 | 1997-12-31 | 0.05 | 0.04 | -0.01 | 20 | ||
1997-11-12 | 1997-09-30 | 0.07 | 0.07 | 0.0 | 0 | ||
1997-07-31 | 1997-06-30 | 0.09 | 0.09 | 0.0 | 0 | ||
1997-04-30 | 1997-03-31 | 0.08 | 0.09 | 0.01 | 12 | ||
1997-01-30 | 1996-12-31 | 0.07 | 0.08 | 0.01 | 14 | ||
1996-11-08 | 1996-09-30 | 0.06 | 0.04 | -0.02 | 33 | ||
1996-07-31 | 1996-06-30 | 0.07 | 0.08 | 0.01 | 14 | ||
1996-05-02 | 1996-03-31 | 0.05 | 0.07 | 0.02 | 40 | ||
1996-02-01 | 1995-12-31 | 0.03 | 0.04 | 0.01 | 33 | ||
1995-11-08 | 1995-09-30 | 0.02 | 0.02 | 0.0 | 0 |
Hologic Corporate Management
Mark Irving | VP Secretary | Profile | |
Paul Malenchini | Chief Officer | Profile | |
Peter Dunne | Senior Resources | Profile | |
Benjamin Cohn | Principal Chief Accounting Officer | Profile | |
Erik Anderson | Division Solutions | Profile | |
Kevin Thornal | Group Solutions | Profile |
Additional Tools for Hologic Stock Analysis
When running Hologic's price analysis, check to measure Hologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hologic is operating at the current time. Most of Hologic's value examination focuses on studying past and present price action to predict the probability of Hologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hologic's price. Additionally, you may evaluate how the addition of Hologic to your portfolios can decrease your overall portfolio volatility.